# Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

> **NCT06005428** · PHASE2 · TERMINATED · sponsor: **Cardurion Pharmaceuticals, Inc.** · enrollment: 7 (actual)

## Conditions studied

- CPVT1
- Heart Defects, Congenital
- Heart Diseases
- Ventricular Tachycardia

## Interventions

- **DRUG:** CRD-4730
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06005428
- **Lead sponsor:** Cardurion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-11-07
- **Primary completion:** 2025-05-31
- **Final completion:** 2025-05-31
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** The early termination of the clinical trial is due to an internal administrative and business decision, the study is not being terminated for safety reasons.
- **Last updated:** 2025-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06005428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06005428, "Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06005428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*